European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Primary Urethral Carcinoma

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. Epidemiology Aetiology And Pathology
  4. Staging And Classification Systems
  5. Diagnostic Evaluation And Staging
  6. Prognosis
  7. Disease Management
  8. Follow Up
  9. References
  10. Conflict Of Interest
  11. Citation Information
8. Follow Up
  • 1. Introduction
  • 2. Methods
  • 3. Epidemiology Aetiology And Pathology
  • 4. Staging And Classification Systems
  • 5. Diagnostic Evaluation And Staging
  • 6. Prognosis
  • 7. Disease Management
  • 8. Follow Up
  • 9. References
  • 10. Conflict Of Interest
  • 11. Citation Information
  • No elements found. Consider changing the search query.
  • List is empty.

8. FOLLOW UP

Given the low incidence of primary urethral carcinoma, follow-up has not been systematically investigated. Therefore, it seems reasonable to tailor surveillance regimens to patients’ individual risk factors (see Section 6.2). In patients undergoing urethra-sparing surgery, it seems prudent to advocate a more extensive follow-up with urinary cytology, urethrocystoscopy and cross-sectional imaging despite the lack of specific data.

8.1. Research priorities

There are clear gaps in the clinical literature related to the diagnosis, management and follow-up of patients with primary urethral carcinoma. As this is a rare disease, data will likely become available through quality registries and datasets, similar to those currently being set up by the eUrogen initiative.

The Panel identified the following topics as of interest:

  • The (long-term) efficacy of urethral-sparing surgery and chemoradiotherapy for genital preservation in localised and locally-advanced tumours;
  • The prognostic impact of neoadjuvant and adjuvant treatment modalities in locally-advanced disease;
  • The therapeutic benefit and clinical safety of programmed cell death (ligand)-1 inhibitors for the treatment of advanced primary urethral carcinoma;
  • The role of MRI in the local assessment of response to therapy.
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer